Introduction
Serum albumin, a highly abundant extracellular protein in blood plasma and tissue fluids, is a formidable multi-tasker. Due to its high concentration (around 0.6 mM in plasma) albumin makes a major contribution to the colloid osmotic pressure of plasma 1) and serves as a significant reservoir for the signalling molecule, nitric oxide. 2) But the protein is perhaps best known as a transporter molecule for an impressive variety of endogenous compounds, including nutrients such as non-esterefied fatty acids, hormones such as thyroxine and waste products including heme, bilirubin and a range of renal toxins. 1, 3) Because of the remarkable ability of this one protein to bind a structurally diverse set of natural lipophilic anions, it is no surprise to find that albumin can also bind a wide range of drug molecules with a matching physicochemical profile. The propensity of albumin to absorb significant concentrations of drugs in plasma and tissue fluids is the origin of the long-standing pharmaceutical interest in the protein.
The fascinating binding properties of albumin, a 66 kDa monomer, have been studied for over 40 years. These investigations have been very fruitful but hampered by the complexity of the protein, which has multiple binding sites and is known to be rather flexible. 1, 3) Until 1992 there was no high-resolution structural information to provide a framework on which to shape a more detailed interpretation of the binding data. Within the past 10 years or so, however, the Protein Data Bank has been populated with nearly 50 crystal structures of human serum albumin (HSA), either free from ligands or complexed with a range of endogenous or exogenous small molecules. After decades of invisibility, the heartshaped form of HSA is now likely to be familiar to anyone who is conversant with the literature on the protein.
This review provides an assessment of our current understanding of the structure of albumin and discuses show crystallographic studies have been used to elucidate its various functions. Many of the details have already been published in the primary literature and have been reviewed elsewhere. 1, [3] [4] [5] [6] I focus here on the main findings while at the same time attempting to draw out aspects of the work that may have been under-emphasised. With the goal of stimulating future research in this area, an overview of techniques -and some of the difficulties -involved in the crystallographic analysis of albumin are also discussed.
Methods for Crystallographic Analysis of Serum Albumin
Preparation of defatted HSA for crystallisation: Methods for the growth of crystals of albumin were pioneered by Carter and colleagues who obtained diffraction quality crystals of albumins from a variety of mammalian species including humans, baboons, dogs and horses, 7) and went on to publish the first crystal structures of HSA 8) and horse serum albumin. 9) Serum albumin proteins clearly crystallise fairly readily but, although several structures have been solved using protein purified from serum, [10] [11] [12] the availability of recombinant HSAexpressed in yeast 13, 14) -has permitted good quality crystals to be obtained more reliably. In all probability this is due to the greater homogeneity of the recombinant protein; albumin purified from plasma is more heterogeneous because of polymorphisms in the gene between individuals 1) and glycation of the protein during its relatively long lifetime in the circulation. 15) Commercial preparations of recombinant HSA often contain hydrophobic stabilisers that need to be removed prior to crystallisation. For example, material kindly provided to us by Delta Biotechnology Ltd (now owned by Novozymes) was formulated as 250 mg/ml HSA in 145 mM NaCl, 40 mM octanoate and 15 mg/ml Tween-80. This material needs to be defatted by incubating the protein with activated charcoal at low pH using methods established by Chen and colleagues 16, 17) (unless one is planning to co-crystallise the protein with fatty acid ligands -see below). This method can also be used to defat recombinant HSA expressed in Picha pastoris in readiness for crystallisation trials. 18) The purity of the albumin sample is important for successful crystallisation, as is the case when crystallising most proteins. We have found that even highly purified preparations of HSA may still contain a significant fraction (5-20%) of dimers that need to be removed if high quality crystals are to be obtained. 16, 19) These dimers arise due to the formation of an inter-molecular disulphide bond involving Cys-34, the one free cysteine in the protein 19) and can be removed using gel filtration chromatography. The resulting preparations of monomeric HSA appear not to reform significant quantities of dimer over a period of several weeks when stored at 49 C (unpublished data).
Crystallisation of recombinant HSA is usually performed by sitting drop vapour diffusion using 80-150 mg/ml of monomeric protein dissolved in 20-50 mM sodium or potassium phosphate buffer at pH 7-7.5. 7, 10, 16) The need for such unusually high protein concentrations -5-20 mg/ml protein are normally used in crysallisation trials -is probably due to the very high solubility of HSA. Crystals of defatted HSA are generally grown by mixing equal volumes of protein and reservoir solution using sitting drop vapour diffusion over a reservoir of 24-34% (w/v) polyethylene glycol 3350 in 50 mM sodium or potassium phosphate, pH7-7.5. In our laboratory, crystals are grown at 49 C 16, 20) but growth at room temperature is also possible. 7) Crystals normally appear spontaneously within a few days though we routinely use streak or micro-seeding to promote crystal growth, 21) since this gives a more reliable yield of crystals. Typically for each new batch of purified protein a screening tray will be set up covering a range of PEG 3350 concentrations to determine which is optimal for crystal growth. The remainder of the batch is then set up at this PEG concentration and the drops are seeded after they have been equilibrated for 3-5 days. Even with this procedure the yield of crystals is rather variable and typically only 10-30% of the drops set up will produce crystals of a useful size (maximum dimension À0.15 mm) for room temperature data collection.
Preparation of complexes of HSA with small molecule ligands for crystallisation: The crystals of defatted HSA obtained following the procedures described above can yield high-resolution diffraction data (up to at least 2.2°A). Unfortunately the crystals are too fragile to allow small molecule ligands to be soaked into them and tend to fracture, 10) although we did have some success with a volatile anaesthetic. 16) This limitation means that HSA-ligand complexes must be co-crystallised: in other words the HSA-ligand complex is prepared prior to crystallisation. There is a variety of ways to achieve this, which differ depending on the nature of the ligand to be examined. Since success at crystallisation is critically dependent on the homogeneity of the sample to be crystallised, we generally adopted methods to ensure full occupancy of the binding sites on the protein. The experimental design therefore demands some prior estimation of binding affinity and the likely number of sites so that the mole ratio of ligand to protein can be chosen to ensure saturation of the protein. In the case of fatty acids, for which it was anticipated that there would be several sites, we used fatty acid to HSA mole ratios of between 10:1 and 40:1 (higher ratios were used for shorter fatty acids that bind with lower affinity). 19, 22, 23) For other endogenous ligands which have a single primary site (e.g. hemin, bilirubin) we used mole ratios in the range 1:1 to 3:1. 24, 25) In the case of drugs for which there are usually only one or two sites, a 5:1 mole ratio of drug to protein was generally adopted. 20) Fatty acids are very poorly soluble in aqueous solutions but it proved sufficient to mix well-dispersed suspensions of fatty acids with protein solutions to prepare HSA-fatty acid complexes. 19, 22, 23) For example, in the case of myristic acid, the fatty acid was prepared at a nominal concentration of 2.5 mM, generating a very turbid suspension. This mixture was vortexed and heated by short incubations in a microwave oven to around 509 C to aid disper-sal of the fatty acid. The suspension was allowed to cool to around 379 C before being added to HSA at the desired mole ratio and complex formation achieved by incubation of the mixture at room temperature for at least an hour. After this time, excess unbound fatty acid not in solution was removed by centrifugation and the complex washed with a solution containing a known concentration of fatty acid (100 mM in the case of myristic acid) by performing up to 3 cycles of dilution and concentration in an 10 kDa MW cut-off centrifugal concentrator. 19, 23) Although HSA has a MW of 66 kD, we experienced significant leakage of the protein through the membrane of concentrators with a 50 kDa MW cut-off. The precise reason for this is unknown but the leakage may arise because very high protein concentrations (around 100 mg/ml) are well above those (1 mg/ml) normally used to test these devices.
For ligands such as hemin or bilirubin, which are also extremely insoluble in aqueous solution but where a lower mole ratio is used to form complexes with HSA, the ligand was dissolved in dimethyl sulfoxide (DMSO). The DMSO solution containing the ligand was then mixed directly with the aqueous solution of HSA (in phosphate buffer). In these experiments the volumes and concentrations were controlled such that HSA was not exposed to a final DMSO concentration greater than 14% (v/v) 24, 25) (although the effect of higher concentrations on the protein on the outcome of crystallisation trials was not tested). Following overnight incubation at room temperature to allow the complex to form, the DMSO concentration was reduced to less than 0.1% (v/v), again by cycles of dilution with buffer and re-concentration in a centrifugal concentrator. This was to prevent DMSO from perturbing the crystallization conditions.
For most drugs an aqueous solution of the drug was prepared for complexing at a 5:1 drug:HSA mole ratio. 20) After incubation at room temperature for 1-16 hours the free drug concentration was typically fixed at 0.1 mM by repeated cycles of concentration and dilution. In one or two cases DMSO (for oxyphenbutazone, phenylbutazone and indoxyl sulfate), or methanol (for diazepam and ibuprofen) solution of the drug was used in complex formation and the complexes treated as described above to reduce the concentration of the organic solvent to less than 0.1%(v/v). 20) For propofol, a high concentration of drug was maintained throughout complex formation and crystallisation. 16) In all cases crystallisation of HSA-ligand complexes was achieved using exactly the same protocol and conditions described above for defatted HSA crystals.
Using crystals of HSA-myristic acid complexes for drug soaking: The crystals we obtained with HSAfatty acid complexes (space-group C2) were physically much more robust than defatted HSA crystals (spacegroup P1) and permitted drug soaking experiments to generate ternary HSA-myristate-drug complexes. In general, crystals of proteins contain large solvent channels that allow rapid diffusion of small molecules; as long as the entrance to the binding pocket is not occluded by contacts between adjacent proteins in the crystal, it is often possible to add ligands to proteins in the crystalline form. In the case of HSA this approach works well for compounds that bind specifically to drug site 1 in subdomain IIA, since this is a low-affinity fatty acid binding site 26) and -under the experimental conditions usedthe drugs are often able to displace the bound fatty acid. 16, 19, 20, 27) This approach has the distinct advantage that a large batch of crystals can be prepared and used for soaking experiments with a range of different compounds.
However, soaking does not work in all instances; larger compounds such as hemin, bilirubin, thyroxine and tolbutamide, all of which have high affinity for the protein, were unable to bind to crystallised HSA-myristate complexes. Although these compounds are small enough to penetrate the solvent channels, they are presumably unable to access their binding sites on the protein, either because of steric hindrance due to close packing of proteins in the crystal or because crystal contacts reduce the breathing motion of the protein needed to permit binding. An interesting exception to this general observation is iodipamide (MW 1140 Da) which, although it is larger than thyroxine (MW 777 Da) and also binds to drug site 1 in sub-domain IIA, is able to access the site; 20) it may be that the greater flexibility of the iodipamide molecule allows it to wriggle into position.
The use of HSA-myristate crystals in soaking experiments is also ineffective for drugs specific for drug site 2 in sub-domain IIIA since this is a high-affinity fatty acid binding site; we were unable to find experimental conditions that would allow drugs to displace the bound fatty acid from this pocket. However, there may be another route. The HSA-thyroxine complex crystallised in a P21 space group 18) with a unit cell that has also been observed for defatted HSA, 7) a crystal form that appeared to us physically robust. Although thyroxine is observed to bind to drug site 2, this is a low affinity site for the hormone and back-soaking of crystals in PEG 3350 solutions lacking thyroxine but containing diazepam, a site 2 drug, allowed the drug to be inserted into the binding site in these crystal (J. Ghuman and S. Curry, unpublished observations). For reasons not clear to us, we were unable to obtain this crystal form with defatted HSA, even after cross-seeding with HSA-thyroxine crystals and we therefore resorted to co-crystallisation to examine the binding of site 2 drugs to the albumin. However, in principle, preparation of HSA-thyroxine crystals 18) or better still defatted HSA crystals 7) in this P21 space-group offers a route to drug soaking experiments with site 2 compounds. X-ray data collection: Most published structures of HSA have been solved using X-ray diffraction data collected at room temperature from crystals mounted in sealed glass capillary tubes. This method of data collection is now rarely used thanks to the development of cryo-cooling techniques that allow crystals to be cooled to 100K in a stream of nitrogen gas during exposure to an X-ray beam. Cryo-cooling greatly reduces the impact of radiation damage during the experiment, permits much smaller crystals to be used for data collection and should yield higher resolution data. 28) With the advent of micro-focus beamlines at third generation synchrotrons it is now possible to collect diffraction data from crystals only around 10 mm thick (e.g. see reference 29) ). However, application of cryo-cooling to HSA crystals has proved problematic. In our experience cooling to 100K usually resulted in significant degradation of the order of the crystal lattice that increased mosaic spread and reduced the useful resolution of the data. Progress in this area has been made elsewhere and there are now several reports of HSA structures determined using data collected from cryo-cooled crystals, 12, 28, 30, 31) though unfortunately some published reports lack an account of how cryo-cooling was achieved. 12, 28) In contrast, Lejon and colleagues describe the use of either mineral oil or addition of 20% glycerol to the crystal harvest buffer to achieve cryo-cooling that permitted the determination of high-resolution structures (2.5-2.7°A) of complexes of HSA with a small domain from a bacterial surface protein. 30, 31) Elsewhere, 10-15% ethylene glycol has also been used as a cryo-protectant for crystals of defatted HSA grown from PEG 6000 (Kim L. Hein, Jesper V. Møller, Ulrich Kragh-Hansen, and Poul Nissen, unpublished data). In both cases the crystals were flash cooled in liquid nitrogen after incubation in the cryo-buffer.
It is nonetheless possible to collect high resolution Xray diffraction data from HSA crystals at room temperature as long as reasonable precaution is taken. The best quality data are collected using intense X-ray beams provided at dedicated synchrotron sources. In our experience crystals of maximum dimension no less than 0.15 mm are generally required to obtain usable data, though larger crystals are of course preferable; with careful seeding it has been possible to obtain HSA crystals up to 1 mm in size.
Defatted HSA and HSA-fatty acid complexes crystallize in distinct space-groups, reflecting different ways of packing the molecules into an ordered lattice. 7, 10, 16, 23) In our laboratory defatted HSA most commonly crystallized in a P1 space-group, 16, 20) whereas HSA-fatty acid complexes crystallise in C2. 23) In both cases there is variability in unit cell parameters for different crystals. This nonisomorphism makes it difficult to combine data from more than one crystal and our room temperature data were therefore always obtained with short exposure times (around 1 s at a second generation synchrotron) to allow complete datasets to be obtained from single crystals before the onset of excessive radiation damage. This strategy is workable, though the absence of any crystallographic symmetry in the P1 space-group of the defatted HSA crystal means that a minimum of 1809of data (typically 180 exposures with a 19crystal rotation in each exposure) is required. Even with this minimal exposure regime, there is appreciable radiation damage in the latter portion of the dataset.
Our working practice is to mount crystals in sealed, siliconised glass capillaries at the laboratory before transporting them in insulated boxes to the synchrotron. The crystals may degrade in appearance during ligand soaking or the manipulation required to mount them in capillaries. Although appearance can be misleading, it is not uncommon to find evidence of a secondary lattice in the Xray diffraction pattern, indicating that the crystal is actually formed from two crystals, due either to growth defects or fracturing of the crystal into two or more pieces that are no longer perfectly aligned. In such cases it may nevertheless be possible to process the diffraction data from the dominant lattice, so crystallographers should always adopt an optimistic frame of mind when collecting data from HSA crystals! The crystal structure of HSA The three helical domains of HSA are arranged in a heart-shaped molecule. Each domain contains ten helices but is evidently composed of two sub-domains (A and B) containing six and four helices respectively linked by a stretch of extended polypeptide (Fig. 1a) . In domains I and II, the C-terminal helix of the B sub-domain is contiguous with the N-terminal helix of the succeeding A sub-domain; in this way, domains I and II are connected by a single long 9-turn helix (residues 173-205), as are domains II and III (residues 366-398). The polypeptide connections between domains and sub-domains are further buttressed by non-covalent contacts.
Although the three domains are similar in structure, 8, 19) the two domain interfaces are not (Fig. 1b, c) . This means that the orientation of domain II relative to domain I is different from the orientation of domain III relative to domain II, an asymmetric construction that contributes to the asymmetric distribution of binding sites for fatty acids 19) (see below). Although HSA can partially unfold in acidic conditions, 3) the heart-shaped conformation revealed by crystallography is very likely to be the structure of all mammalian albumin molecules when free in solution at normal physiological conditions. This contention is supported by the finding that similar heart-shaped conformations have emerged from crystallographic analysis of equine serum albumin 9) and solution studies on bovine serum albumin using small-angle X-ray scattering 32) and phosphorescence depolarization. 33) Moreover, crystallographic work has shown that the heart-shaped conformation of HSA is maintained -albeit with some minor differences in relative orientation of the component domains -even in the presence of a wide variety of ligands and under different crystallisation conditions. 18, 23, 24, 31) That said, the crystallographic work has nevertheless revealed some variation in the relative orientation of the domains that probably arises from inherent flexibility of the molecule, although the overall heart shape is always maintained. 6, 22, 23) The structure of defatted HSA has been determined in three distinct crystal forms, each of which has different packing contacts between the proteins in the crystal. 8, 10, 16) Overall these three structures are very similar but differ mostly in the positioning of domain III relative to the rest of the molecule (see Fig. 2a in reference 4) ) which pivots from the centre over an angular range of about 79 . Moreover crystal structures of HSAfatty acid complexes show that binding of these ligands results in somewhat larger movement of domains I and III which rotate outwards relative to domain II by about 169when the protein is saturated with fatty acids that occupy the seven binding sites common to medium and long-chain fatty acids. The binding of fatty acids stabilizes a conformation that, at 90°A, is 10°A wider than defatted HSA. Intriguingly the formation of a HSA-fatty acid complex with a sub-saturating amount of fatty acid (four moles of myristate per mole of HSA) produced a conformational state intermediate between defatted HSA and the fully loaded HSA-myristate complex. 6, 22, 23) Interpreting flexibility in crystal structures: While on the subject of conformational variability in HSA, a few additional comments should be made on the impact of polypeptide flexibility or dynamics on crystallographic analysis of the protein. Although conformational variability is a factor that often impedes protein crystal growth, the plasticity of HSA does not prevent crystallographic analysis from revealing its structure in tremen-dous detail. Most HSA crystal structures have been determined to a high-resolution limit between 2 and 3°A, which means that the positions and orientations of mainchain and side-chain atoms are known with some confidence.
However, some parts of the protein are better known than others. In general, amino acid side-chains and polypeptide loops exposed on the surface of the protein may be rather flexible and adopt a number of different positions, even within the crystal. Since a crystal structure is an average of all molecules in the crystal, the flexible portions therefore appear`blurred' (rather like a fast-moving object in a photograph); in effect the electron density for these parts of the structures is smeared out and can be difficult to interpret in terms of a single conformation of the polypeptide chain. This makes it difficult to build an accurate atomic model, so these parts of the structure should be interpreted with caution.
How can the general user detect such portions of the structure? In a crystallographic model dynamic features are associated with higher temperature or B-factors, parameters recorded for every atom in the PDB file that describes the structure (conventionally listed as the right hand column of numbers). Although B-factors are used to model both static and dynamic disorder (static disorder reflecting slight mis-alignments of the proteins throughout the crystal), variation in the B-factor gives indication of the relative flexibility of different parts of the protein.
Parts of the structure with high B-factors can be revealed by B-factor dependent coloring in most molecular visualization software (e.g. PyMOL 34) ). In Figures 1d and 1e the portions of two HSA structures with high B-factors are colored red; these parts of the structure have been built into weak electron density and their conformations are therefore less certain. It is also possible to examine the electron density map directly using files downloaded from the electron density server, 35) though this requires some familiarity with programs such as O, 36) that are capable of displaying these maps.
One may also need to exercise caution in examining the parts of the crystal structure that have low B-factors, since sections of the polypeptide chain that are normally flexible in solution may still be fixed in a single conformation if they are involved in contact between proteins in the crystal. This problem has been mitigated for HSA because the structure has been determined in a variety of different crystal forms. As mentioned above, there are three independent structure determinations, each solved in a different packing environment; moreover, complexes of the protein with fatty acids, 19, 25) thyroxine 18) and a bacterial albumin-binding domain, 31) have also been determined in different crystal forms and comparison of these structures has revealsed some general patterns. The highest B-factors are usually found within the linker between sub-domains IIIA and IIIB (residues 502-516) and the short linker (residues 559-566) connecting the C-terminal pair of helices. Indeed these helices themselves show some mobility; in some cases the C-terminal helix (residues 565-585) has been largely omitted from the model because the electron density is invisible, thus preventing accurate placement of the atoms. 18, 31) On defatted HSA structures the loop connecting the C-terminal helices of sub-domain IA (residues 76-84) also generally has high B-factors (Fig. 1d) and has sometimes been partially omitted from deposited models. 18, 31) Fortunately most features affected in this way are on the periphery of the structure and not involved in ligand interactions. The primary ligand binding sites are mostly found in the cores of the protein sub-domains and generally have good electron density.
Fatty Acid Binding
Crystallographic analysis has brought much clarity to the investigation of how the primary endogenous ligand binds to HSA by revealing the locations and architecture of the fatty acid sites on the protein. Structures of HSA complexed with medium and long-chain saturated fatty acids (with chain lengths C10, C12, C14, C16 and C18) and two unsaturated fatty acids, oleic acid (C18:1) and arachidonic acid (C20:4) have been determined, 22, 23) providing a useful database of structures. Seven binding sites common to all these fatty acids have been identified, and shown to be distributed across the protein 22, 23) ( Fig.  1e) . Shorter chain fatty acids (C10-C14) were found to bind at several additional locations on the protein, though these are likely to be low affinity sites, only occupied because of the very high fatty acid concentrations used to prepare the HSA complexes.
23)
The seven common sites display considerable topological differences and are contained either within a single sub-domain (site 1, 4, 5 and 7), at the interface between two domains (sites 2 and 3), or at the interface between two subdomains within the same domain (site 6) (Fig. 1e) . The pockets are flattened slots (sites 1, 3, 7), narrow tunnels (sites 2, 4, 5) or surface trenches (site 6).
In fatty acid sites 1-5 the carboxylate group of the bound lipid is anchored by interactions with basic or polar groups at the pocket entrance. The methylene tail extends into a pocket that is usually pre-formed, though binding appears to be associated with slight expansion of the occupied domain. 6, 19, 23) For the long, narrow sites 2, 4, 5 and 6, the longer fatty acids simply fill up more and more of the pocket in a fairly linear fashion, although the presence of multiple cis-double bonds in arachidonic acid introduces significant kinking of the methylene tail. 37) At sites 1, 3 and 7, which are shorter and wider, the methylene tails of longer bound fatty acids bend around the contours of the pocket.
Prior to the crystallographic work, NMR titration experiments indicated ionic anchoring of the fatty acid carboxylate to be a characteristic feature of the three high-affinity binding sites on albumin. 38, 39) However, it was not immediately apparent from the structure as to which three of the five sites with ionic anchors for the fatty acid carboxylate had high affinity. 6) Structure-based mutagenesis has revealed that for long-chain fatty acids such as palmitic acid (C16:0) -commonly found associated with HSA in vivo 40) -sites 2, 4 and 5 have the highest affinity. 26, 41) These three sites, as well as being long and narrow, are the most enclosed pockets on the protein; it appears that there may be an energetic penalty to binding in a bent conformation. Interestingly, studies with medium chain length fatty acids indicate that these bind to an overlapping but not quite identical sub-set of sites with high affinity 42) -see below.
Although most of the binding sites are pre-formed, combinations of some remarkable local and global conformational changes are needed for HSA to absorb its full complement of fatty acids. Occupation of fatty acid sites 2 and 3 at the inter-domain interfaces appears responsible for driving the large conformational change in HSA that is observed on fatty acid binding. In each case conformational change is in fact required to construct the binding pocket from two separate half-sites. Site 2 is formed from sub-domains IA, IB and IIA and straddles the interface between domains I and II. The binding site is only formed when the methyl end of the binding pocket in domain I rotates (by about 169 ), to line up with the compartment formed largely by sub-domain IIA that interacts with the carboxylate end of the fatty acid, allowing the lipid to bind in a linear conformation. The carboxylate head-group is coordinated by Tyr 150 (IB) Arg 257 (IIA) and Ser 289 (IIA), while the methylene tail extends into a hydrophobic pocket in sub-domain IA: the bound fatty acid acts as a stabilising pin to lock the altered conformation of the protein. In defatted HSA this pocket sits on top of the apolar side-chain of Leu-251, an interaction that appears to stabilise the relative orientation of domains I and II (see Fig. 2 in reference 6) ). Although this interaction has to be ruptured for fatty acids to bind, the energetic penalty is not sufficient to prevent site 2 from binding the lipid with high affinity. 26) The formation of fatty acid site 3 is quite different. In this case binding of fatty acid can only occur after a salt bridge between the side-chain carboxylate of Glu 450 and Arg 348 in defatted HSA (Fig. 2a) is broken and replaced by a similar interaction between Arg 348 and the carboxylate group of the lipid (Fig. 2b) . Glu 450 is located in the middle of helix 4 of sub-domain IIIA (residues 444-467) and, rather surprisingly, its displacement by fatty acid leads to local twisting of the helix about its axis (Fig. 2c) . This results in a significant distortion of the helix backbone in the immediate vicinity of Glu 450 and Asp 451. The distortion rotates the position of Asp 451 to within salt-bridge distance of Lys 195 (2.6°A
) and may contribute to coupling of the rotations of domains I and III (Fig. 2b) . However, it is difficult to quantitatively assess the impact of domain-domain contacts on conformational change in comparison to the more direct and evident effects of fatty acid binding.
The same global conformational changes have been observed for all medium and long-chain, saturated and unsaturated fatty acids (C10-C20). 19, 22, 23) . In every case the complex was prepared at saturating amounts of fatty acid so as to assure atteining the end-point of the conformational transistion. Interestingly, as mentioned above, examination of a HSA-hemin-myristic acid complex prepared at 4 moles of fatty acid per mole of HSA (and 1 mole of hemin) produced a structure intermediate between the defatted conformation and that observed for HSA when fully loaded with fatty acid. 25) This occurred even though there was on average only partial occupancy of six of the seven fatty acid sites on the proteins in the crystal (fatty acid site 1 in sub-domain IB was occupied by hemin). The intermediate conformation is due to the subsaturating levels of fatty acid and not to the presence of hemin, because a HSA-hemin-myristate complex formed at higher HSA:fatty acid mole ratios yielded a conformation that was identical to that observed for fully loaded HSA-fatty acid complexes. 28) The crystallisation of this intermediate state can only have been achieved by aggregation of a population of HSA-fatty acid complexes with different distributions of sites occupied by fatty acid, though the increased heterogeneity of the HSA-fatty acid complexes may have contributed to the relatively low resolution diffraction (3.2°A) obtained from these crystals. 25) The function, if any, of the fatty acid-induced conformational change is unknown 4) but there is an impact on drug binding that can be explained by the structure (see below).
An interesting example of local conformational change associated with fatty acid binding occurs at site 1 in subdomain IB. Here the binding pocket is created only after ¿909rotations of a pair of Tyr side-chains (Tyr 138 and Tyr 161) unstacks them to open up a D-shaped cavity for the lipid. 6, 19) The side-chains of the rotated tyrosines assume positions on opposite sides of the flanking walls of this cavity from where they make close contact with the bound fatty acid.
There are one or two differences in the observed modes of fatty acid binding in the structures of HSA-fatty acid complexes solved in our laboratory, compared to those determined elsewhere that should perhaps be noted, even though the reasons for their occurrence remain unclear. In the structure of the HSA-myrisate-hemin complex reported by Carter and colleagues, 28) the position of the carboxylate of the fatty acid bound in site 4 (sub-domain IIIA) is altered by about 2.8°A, so that it can no longer hydrogen bond to Ser 489 23) but instead appears close enough to interact with the side-chain or Asn 391. In addition, in the ternary complex of HSA, decanoic acid and the bacterial albumin-binding GA domain, 30) there is no fatty acid bound to site 5 (subdomain IIIB), even though this has been identified as a possible high-affinity site for this medium chain lipid. 42) Crystallographic analysis of HSA complexes with other endogenous ligands: Fatty acids are the primary cargo of HSA and have the most binding sites of any endogenous ligand. However, other important molecules are also transported by the protein, invariably in one of the fatty acid binding sites. Hemin and bilirubin bind to sub-domain IB (fatty acid site 1) 24, 25, 28) whereas thyroxine binds to sub-domain IIA (fatty acid site 7). 18) The diverse binding capacity of sub-domain IB exemplifies the tremendous versatility of HSA. As mentioned above, binding of fatty acid to this site demands the unstacking of Tyr 138 and Tyr 161 to generate the cavity that accommodates the lipid. This same conformational change is observed on binding of hemin, which fits snugly into the cavity with its pair of propionate groups positioned at the cavity entrance where they can interact with basic residues, a mode of binding that broadly mimics fatty acid binding. However, whereas Arg 117 co-ordinates the carboxylate group of the fatty acid bound to this site, it is not involved in binding of hemin; instead a triad of Arg 114, His 146 and Lys 190 serves to coordinate the two carboxylate groups attached to the porphyrin ring.
The porphyrin ring of hemin makes largely hydrophobic contacts with the sides of the cavity within subdomain IB, though there is also a clear hydrogen-bond between the side-chain hydroxyl of Tyr 161 and the iron atom in the centre of the porphyrin ring. The enclosure of heme in a hydrophobic cavity is of course reminiscent of the construction of the oxygen-binding proteins myoglobin and hemoglobin and has raised the possibility of exploiting HSA-heme complexes as artificial oxygen carriers. Extensive studies by Tsuchida and Komatsu used the structure of the HSA-hemin complex to re-engineer the heme-binding pocket by mutagenesis so as to confer the ability to bind oxygen reversibly. 25, 43, 44) This has been achieved by substitution of Tyr 161 by Phe or Leu to remove the H-bond to the porphyrin Fe atom, allowing oxygen to bind without oxidising the heme group; other mutations in the vicinity of the oxygen binding site have also been made to improve the binding kinetics. (See paper by Tsuchida, Komatsu et al. in this issue). The ability of HSA to bind porphyrin compounds can be exploited in other interesting ways: for example, HSA complexed with Zn-porphyrin IX was shown to catalyse the photosensitized reduction of water to hydrogen. 45) These studies exemplify how knowledge of the structure facilitates the development of novel applications for albumin.
One breakdown product of heme is bilirubin, a toxic and highly lipophilic molecule that is transported by albumin for disposal in the liver. Although their chemical structures are closely related and they bind to the same site in sub-domain IB on HSA, they do so in strikingly different ways. In particular recent crystallographic work has shown that bilirubin binds without Tyr 138 and Tyr 161 unstacking from the conformations they adopt in defatted HSA. 24, 25) This means that the binding site has a very different shape to that occupied by fatty acids or he-min.
There is an important caveat to this assertion in that the crystal structure of the HSA-bilirubin complex appears to contain the 4Z,15E-bilirubin-IXa isomer 24) produced when the physiologically predominant dark form 4Z,15Z-bilirubin-IXa is exposed to light. 46, 47) . Although the 4Z,15Z-bilirubin-IXa isomer was used in crystallisation experiments, unavoidable exposure to light during crystal handling and data collection may have induced photo-isomerisation. Modelling studies suggest that 4Z,15Z-bilirubin-IXa could also bind to subdomain IB in much the same way as 4Z,15E-bilirubinIXa, an assignment that would be consistent with some of the binding data for bilirubin (see ref. 24) for discussion), but a definitive determination of the location of the 4Z,15Z-bilirubin-IXa demands further experiments.
4Z,15E-bilirubin-IXa binds in an extended twisted conformation, lying across the pair of stacked tyrosines, making hydrogen bond contact with one of them (Tyr 138). As with hemin the propioniate groups are located close to the pocket entrance but bilirubin binding relies on a completely different set of basic residues for coordination of its carboxylate groups. The rubin carboxylates are coordinated by Arg 117 and Arg 186, whereas those in hemin interact with Arg 114, His 146 and Lys 190. This finding represents yet another instance of the conformational adaptability of the protein.
The steroid antibiotic fusidic acid can also occupy the bilirubin binding pocket, which would explain its observed ability to competitively displace 4Z,15Z-bilirubin--IXa from HSA. 24, 48) The drug fills the binding cavity in more or less the same way as 4Z,15E-bilirubin-IXa (see Fig. 4a in reference 24) ). It seems possible that bile acids, endogenous steroid compounds that share structural similarities with fusidic acid and are known to associate with albumin, 1) may also bind preferentially to sub-domain IB. This needs to be tested directly but competition-binding assays with fusidic acid (or hemin) would be a straightforward way to explore this hypothesis.
Co-crystallization of HSA with thyroxine revealed four binding sites, one in sub-domain IIA (drug site 1), one in sub-domain IIIA (drug site 2) and two in sub-domain IIIB. 18) The physiological relevance of some of these sites is questionable since HSA is only a tertiary carrier of thyroxine in plasma 1) and most binding studies are consistent with there being one or two high-affinity sites. 49) The occupancy of so many sites is one of the prices paid by crystallographers who tend to use high ligand concentrations to ensure homogenous complexes for crystallisation. At least one binding site in sub-domain IIIB appears to be an artefact of crystallisation since the thyroxine ligand receives stabilising contacts from a second protein in the crystal. 18) . The binding of thyroxine to sub-domain IIA is of greatest interest since mutations at this site are responsible for greatly enhancing the affinity of the protein for the hormone, leading to a genetic condition known as familial hyperthyxroxemic dysalbuminemia (FDH). 50) Carriers of this mutation have very high total levels of thyroxine in their blood because of the increased binding affinity (though the free concentration is normal). 51) Thyroxine is a relatively large compound compared to many of the drugs observed to bind to this sub-domain (drug site 1) 20) and fits very snugly within the pocket, projecting its polar aminopropionic head-group out of the pocket entrance. The affinity enhancement responsible for FDH is usually due to mutations of Arg 218, generally to amino acids with smaller side-chains (e.g. Pro or His). Structural studies on FDH mutants of albumin (carrying either of the substitutions R218P or R218H) reveal only very modest conformational changes within the binding site in sub-domain IIA. 18) This results in a very small shift of the bound hormone in the pocket: it appears that the affinity increase may be due to relaxation of steric hindrance at the binding site. However, the subtlety of the structural change means it is difficult to be precise about the molecular basis of the enhanced affinity; dissection of functional differences from structural work can sometimes be rather frustrating.
A very interesting example of a protein-protein interaction involving HSA was reported by Lejon and colleagues, who solved the crystal structure of HSA complexed with the small GA domain from the PAB surface protein of the anaerobic bacterium Finegoldia magna.
31)
The triple helical bacterial GA domain adheres to an exterior flank of domain II, making polar and apolar contacts with both A and B sub-domains. Curiously, HSA appears to have retained some fatty acid in fatty acid sites 6 and 7 even after purification, which has been interpreted as decanoic acid; one of the decanoic acid molecules bound to site 6 (at the IIA-IIB interface) actually forms part of the contact surface with the GA domain but makes no specific polar interactions with it (see Fig. 4 or reference 31)). Despite the presence of a small amount of fatty acid (and contrary to what is stated in the paper 31) ), the HSA structure is most similar to the conformation of defatted HSA. 8, 10, 16) Nevertheless, the mode of binding of GA is unchanged even when albumin is deliberately loaded with this medium chain fatty acid and adopts a conformation very similar to that observed for other HSA-fatty acid complexes. 30) HSA also interacts with other proteins as part of its daily round through the circulation. These include albondin (or gp60), the receptor believed to mediate transcytotic movement of the protein across the endothelial barrier 52, 53) and the MHC-related receptor for IgG (FcRn), which helps to rescue albumin from lysosomal degradation, thus prolonging its lifetime. 54, 55) However, structures of the complexes of HSA with these proteins have yet to be reported. Co-crystallisation of HSA with FcRn presents particular challenges since the interaction is greatest at a pH or 5.5 or less, 55, 56) a regime that is known to involve structural change in albumin. 1, 3) Structural studies should illuminate the metal binding properties of albumin. As with other types of ligand, HSA binds to a diversity of metal ions at a number of sites. The protein plays a role in zinc transport and may help to reduce the toxicity of copper in some mammals. 57) Several metal binding sites have been located on the protein by methods other than direct structure determination. The N-terminus of the mature protein binds Cu(II) and Ni(II), 58) whereas Zn(II) preferentially occupies a site at the interface between domains I and II that involves His 67.
59)
A site of undetermined location binds Cd(II), and Cys 34, the only free thiol in the protein, binds to compounds containing Au and Pt.
57)

Drug Binding
In addition to the panoply of natural compounds that associate with the protein, albumin also binds a wide variety of drugs, an issue of great interest to the pharmaceutical industry. Binding to albumin may aid dispersal of drug molecules because -as with endogenous compounds -association with albumin overcomes the problem of low solubility. But if the binding of drugs to albumin is too tight, such that more than 99% of the administered dose is bound to the protein, this may greatly reduce the free, active concentration and ultimately impede delivery of the drug to its site of action. Moderation of the affinity of lead compounds for albumin is often an intrinsic part of drug design.
As with endogenous compounds, it was difficult to get a precise grasp of the drug binding properties of the protein prior to the advent of structural analysis. In the mid 1970s binding studies revealed the presence of two primary and non-overlapping binding sites on the protein, 61) a finding that has stood the test of time and influenced many subsequent studies. Most recent work has focused on developing high-throughput methods to assay drug binding, [62] [63] [64] [65] [66] so that quantitative structure-activity relationships (QSARs) may be developed to allow modelling and prediction of drug binding to albumin. [67] [68] [69] [70] [71] Although such models have been very informative, they may lack accurate predictive power because they do not explicitly account for the impact on drug binding of structural features of the binding sites on HSA.
The acquisition of structural data on HSA-drug complexes has therefore been a strong motive for crystallographic groups hoping to shed light on the molecular basis of the protein's ability to bind such a wide variety of ligands. 8, 12, 20, 30, 72) Carter's initial study, although done at low resolution, clearly established that drug sites 1 and 2 are located in sub-domains IIA and IIIA respectively. 8) Our group has gone on to determine the structures of over two dozen HSA complexes with drugs or drug-like small molecules 16, [18] [19] [20] 27) and has been joined in this effort more recently by groups in China 11, 12) and Sweden. 30) Anecdotally, I understand that crystallographic analysis of HSA-drug complexes has now been embraced by the pharmaceutical industry. One company has also adopted an NMR-based approach to the investigation of HSAdrug binding using expressed domain III fragments to study binding of drugs to site 2 64, 72) and, in at least one case, succeeded in exploiting this information to reduce excessive albumin binding without severely compromising drug efficacy. 73) Collectively this work has produced a veritable atlas of drug binding sites on the protein and brought new clarity to our understanding of HSA-drug interactions. It provides a valuable resource for the design and interpretation of mutagenesis and binding experiments to probe drug interactions with the protein. 26, 41, [74] [75] [76] There is not space here to provide a full account of all the all findings to date, which have in any case been discussed in some detail in the original papers.
Drug sites 1 and 2 are structurally similar to the extent that both are primarily composed of six-helix A-type subdomains (IIA and IIIA respectively). Both sites comprise largely apolar cavities with defined polar features and entrances framed by helices 1, 2 and 6 of the sub-domain.
However, the similarity ends there. For a start the two sites have different``packing environments'' with respect to the rest of the protein. Whereas the entrance to subdomain IIA faces sub-domain IIIA, the entrance to site 2 is completely open to solvent (Figs. 1 and 3) . Moreover, site 1 is more complex in its construction: three subdomains, IB, IIB and IIIA, all contribute to the architecture of drug site 1: the polypeptide that leads into helix 3 of sub-domain IB (residues 148-153) closes off the top of the site, and, in addition, there is an extension of site 1, stabilized by residues from sub-domains IIB and IIIA, that is accessed by some compounds (e.g. indomethacin, iodipamide) 20) ( Fig. 3a, c) . In contrast, drug site 2 only benefits from some close contacts near the pocket entrance with sub-domain IIB. In particular salt-bridges from Glu 450 and Arg 485 (in IIIA) to Arg 348 and Glu 383 respectively (in IIB) serve to stabilize one end of the binding site (Fig. 3b) .
Because of the extension in drug site 1, it is more voluminous than site 2. Although most drugs bind in the main chamber within sub-domain IIA, with their major aromatic groups pinned between the side-chains of Leu 238 and Ala 291, there is considerable variation in the positioning of different compounds within the confines of the pocket. This variability is permitted in part by the sheer size of the cavity. Most compounds examined to date do not fill the pocket completely and it is likely that some of the binding energy derives from contacts with bound water molecules, which have been observed in some cases. 16, 20, 27) Higher resolution studies (closer to 25) and 3b9m 12) respectively. 2°A) will be needed to map out the water-mediated contacts in greater detail. The versatility of the pocket also derives from variable adjustments of the side-chains lining the cavity when different compounds bind. In general these adjustments are quite small, although it is not unusual to see large excursions of the Arg 218 and Arg 222 side-chains at the entrance to the pocket (e.g. see Fig. 3 of reference 20) ). The general specificity of drug site 1 is readily explained by its structure. In particular, residues Tyr 150, His 242, Arg 257 on one side and Arg 218 and Arg 222 on the other are positioned in the center of two apolar chambers and are well placed to coordinate binding of compounds with centrally located negative or electronegative features (Fig. 3a) . The preference for flat aromatic compounds arises because these fit snugly between Leu 238 and Ala 291 in the centre of the pocket.
However, it should be noted that not all drugs bind in this main cavity of site 1. For example, indomethacin binds exclusively in the lower extension, forcing a large rotation of Trp 214 to provide access. 20) Indeed the size and versatility of drug site 1 has been underscored by the finding that indomethacin binds at drug site 1 along side some compounds that occupy the main chamber (e.g. phenylbutazone and azapropazone). 20) More recently a different extension to drug site 1 has been mapped out by a study showing that the HIV drug AZT (3?-Azido-3?-deoxythymidine) binds an upper compartment of the site, right at the interface with sub-domain IB 12) ( Fig. 3c) . Parenthetically, the binding of other anti-HIV drugs to drug site 1, in close proximity to the heme binding pocket in sub-domain IB, is considered to explain the co-oper-ative interaction between these two sites, 77, 78) although a detailed mechanism has yet to be determined.
Drug site 2, as well as being more compact, only has a single dominant polar patch near the pocket entrance, centred on Arg 410 and Tyr 411 (Fig. 3b) . This arrangement accounts for the general preference of this site for aromatic compounds with peripherally located negative or electronegative features. Again, there are variable side-chain adjustments that accompany the binding of different compounds, most notably the displacement of Leu 387 and Leu 453 to accommodate the benzyl moiety of diazepam 20) ( Fig. 3b) . Conformational changes induced by fatty acid binding have large impact on drug site 1. In particular fatty acid binding diverts Tyr 150 and, to a lesser extent, Arg 257 out of the pocket so that they can interact with the fatty acid bound to fatty acid site 2. 20) This alters the structure of one flank of the binding site, although it retains a largely polar character. In most cases where this has been examined (warfarin, azapropazone, phenylbutazone) there is little impact on the location and orientation of the bound drug, although evidence suggests that there may be a modest enhancement of binding affinity. 79) In striking contrast, the orientation of oxyphenbutazone is rotated by about 1809in the pocket when fatty acid site 2 is occupied. 20) Though the impact of fatty acids on HSA affinity for the drug has not been measured, this finding underscores the unpredictable nature of drug interaction with the protein. The effect of fatty acids on drug binding to drug site 1 appears relatively small, but it is a factor that should be given some consideration during lead compound development.
Fatty acids compete directly with site 2 drugs for binding to sub-domain IIIA. Since this site overlaps with one of the high affinity fatty acid binding sites, site 2 drugs are more likely to be displaced from HSA as fatty acid levels rise. At physiological levels of fatty acid, however, competition with drugs is not likely to be a problem, since the residual concentration of drug binding sites under these conditoins is likely to be sufficient for drug binding.
In addition to the two primary drug binding sites, crystallographic analysis has indicated several other drug pockets on the protein. Recent work shows that fusidic acid binds specifically to sub-domain IB, 24) a secondary binding site for a number of compounds that bind preferentially to drug site 1 (e.g. azapropazone, indomethacin, AZT). 12, 20) Secondary sites for other compounds have also been identified at the interface between sub-domain IIA and IIB (e.g. ibuprofen, diflunisal) and in sub-domain IIIA (e.g. propofol, oxyphenbutazone). 20) Moreover some compounds that bind preferentially to one of the two primary sites, are also observed to bind at the other primary drug site (e.g. tri-iodobenzoic acid, diflunisal, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF)). 8, 19, 20) Despite the voracious capacity of HSA for drugs and the conformational adaptability with which it accommodates different compounds, crystallographic analysis consistently shows that there are no gross alterations in the secondary structure content of the protein on ligand binding, which is consistently around 67% a-helical with no b-sheet. 8) This is true even of fatty acid binding which induces large rigid-body rotation of the protein domains. 6, 19) Thus crystallographic investigation provides no corroboration of claims, usually based on CD measurement 80, 81) that ligand binding results in substantial change in the secondary structure content of the protein.
It seems likely that spectral differences observed in such studies are due to other, unspecified effects that can be difficult to interpret precisely at the molecular level. 82) Despite the enormous amount of detailed information on HSA-drug interactions that has accrued from structural studies, there are many more compounds that are worthy of examination. For example, ongoing work at our laboratory (unpublished data) to examine the binding of dansylated amino acids, fluorescent compounds used widely as markers for drug sites 1 and 2. 60, 83, 84) There is also an outstanding need to integrate structural insight with measurement of binding affinity. Efforts should be made to facilitate routine data collection from crystals of HSA-drug complexes at around 2°A or better, to allow visualization of the details of the bound water structure, an important factor in mediating ligand interactions. A future challenge is to integrate high-resolution structural and binding data so that more rigorous QSARs can be constructed. Some interesting progress in this direction has already been made.
85)
Structure-based Mutagenesis and Competition-binding Studies
The determination of the crystal structure of HSA has facilitated the application of genetic engineering to investigate the protein's function and exploit its transport properties. One approach, reflecting earlier work using proteolysis to dissect the protein 86, 87) has been to generate recombinant fragments containing subsets of the domains or sub-domains of the protein, expressed either in bacteria or yeast. Expression in yeast appears to generate better quality samples [88] [89] [90] ; in bacteria only domain III has been obtained successfully as a fully folded domain. 91) These fragments have been used to identify specific binding sites on albumin or to simplify the structural analysis of the protein by NMR. 41, 72, 73, [88] [89] [90] [91] [92] [93] While dividing the protein into smaller segments in this way has been very useful, attention must nevertheless be paid to the possible introduction of artefacts, since binding of some endogenous and artificial ligands is known to occur at or close to interfaces that are not replicated in sub-fragments.
In addition to fragmentation, the structure has allowed site-directed mutagenesis to be used as a powerful tool to probe functions such as binding of fatty acids, 26, 41, 42) thyroxine, 94) bilirubin 95) and warfarin 74) and the esterase activity of the protein. 76) This has the great advantage of permitting investigations with the intact protein.
However, even with structural information in hand, one must proceed carefully with mutagenesis, as the impact on the stability of the protein may be unpredictable. For example, as part of a study to probe the relative affinities of different fatty acid binding sites, we opted to mutate residues identified as coordinating the carboxylate groups of bound fatty acids, reasoning that these would be located close to the surface of the protein and therefore less likely to perturb the protein structure when mutated. However, incorporation of several such surface mutations (R257M, S287A, R348A, R485A and R485M) yielded proteins too unstable to tolerate the extended incubation at 379 C needed for NMR analysis of fatty acid binding. 26) It is therefore important to complement mutagenesis with characterization of the stability of the resulting mutants.
In our work, an alternative strategy exploiting the growing database of structures of HSA-ligand complexes was used to design targeted competition binding experiments. These relied largely on compounds such as hemin, phenylbutazone and diazepam olready shown crystallographically to bind to a single, defined locus on HSA. 26) This type of site-specific probing using drugs with crystallographically determined binding sites represents a valuable extension of the competition binding approach to determining the sites of attachment of uncharacterised compounds. 61) Notably, NMR analysis of fatty acid binding provided evidence of rapid re-distribution of the lipid between different sites in the presence of competing drug ligands. This is a useful reminder of the highly dynamic nature of HSA-fatty acid interactions, despite their very high affinity for the protein. 1, [96] [97] [98] Thus, as well as revealing all available binding sites for fatty acids on the protein, structural information has allowed the question as to which sites have the highest affinity to be addressed in some detail. As mentioned above, for long chain fatty acids such as palmitic acid (C16), analysis of the impact of mutations on the 1D NMR spectra from 13 C-labelled fatty acid has shown that the primary binding sites are 2 (IA, IB and IIA), 4 (IIIA) and 5 (IIIB) (Fig. 1e) . 26, 41) Another study using equilibrium dialysis to compare the effect of mutations on the binding of shorter fatty acids (C8 to C14) identified sites 4 (IIIA) and 5 (IIIB) as high-affinity binding pockets. However, this investigation gave no evidence that fatty acid site 2 (IA-IIA) had high affinity but rather suggested that site 1 (IB) may be a high affinity site for some medium chain fatty acids. 42) These differences may reflect variation in affinity as a function of chain length but further work is needed to investigate this in more detail. The application of 2D NMR methods to the analysis of fatty acid binding to HSA promises to provide the greater resolution needed to take these investigations forward. 99) NMR investigation of HSA will undoubtedly benefit from the further development of methods to isotopically label the protein, 100) which would allow the technique to be applied at high resolution to the whole protein.
